TuHURA Biosciences (TuHURA Biosciences) Debt-to-Revenue : N/A (As of Dec. 2022)

View and export this data going back to 2050. Start your Free Trial

What is TuHURA Biosciences Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

TuHURA Biosciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2022 was $0.12 Mil. TuHURA Biosciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2022 was $0.02 Mil. TuHURA Biosciences's annualized Revenue for the quarter that ended in Dec. 2022 was $0.00 Mil.

TuHURA Biosciences Debt-to-Revenue Historical Data

The historical data trend for TuHURA Biosciences's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TuHURA Biosciences Debt-to-Revenue Chart

TuHURA Biosciences Annual Data

Trend

Dec21

Dec22

Debt-to-Revenue

N/A

TuHURA Biosciences Semi-Annual Data
	Dec21	Dec22
Debt-to-Revenue	N/A	N/A

Competitive Comparison of TuHURA Biosciences's Debt-to-Revenue

For the Biotechnology subindustry, TuHURA Biosciences's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

TuHURA Biosciences's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TuHURA Biosciences's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where TuHURA Biosciences's Debt-to-Revenue falls into.

TuHURA Biosciences Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

TuHURA Biosciences's Debt-to-Revenue for the fiscal year that ended in Dec. 2022 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(0.117	+	0.021)	/	N/A
	=	N/A

TuHURA Biosciences's annualized Debt-to-Revenue for the quarter that ended in Dec. 2022 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(0.117	+	0.021)	/	0
	=	N/A

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is one times the quarterly (Dec. 2022) Revenue data.

TuHURA Biosciences Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of TuHURA Biosciences's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

TuHURA Biosciences (TuHURA Biosciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TuHURA Biosciences Inc (NAS:HURA) » Definitions » Debt-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

10500 University Center Drive, Suite 110, Tampa, FL, USA, 33612

Website

TuHURA Biosciences Inc is a clinical-stage biotechnology company developing novel personalized cancer vaccines and tumor microenvironment modulators to overcome resistance to current immunotherapies. The company's lead personalized cancer vaccine candidate, IFx-Hu2.0, is designed to prime the activation of the immune system to target and attack tumor cells by making them look like bacteria. Through an intratumoral injection of a gene coding for emm55, an immunogenic bacterial protein that is then expressed on the surface of tumor cells, the immune system is activated, providing a potent, multivalent systemic response against all neoantigens in a patient's tumor.

TuHURA Biosciences (TuHURA Biosciences) Headlines

No Headlines